You can buy or sell ONCE and other stocks, options, ETFs, and crypto commission-free!
Spark Therapeutics, Inc. engages in the research, development, and commercialization of gene therapies. Its product portfolio intends to treat inherited retinal sickness, liver-mediated, and neurodegenerative diseases. Read More The company was founded by Jean Bennett, Beverly Davidson, Katherine A. High, Jeffrey D. Marrazzo, J. Fraser Wright, and Jennifer Wellman on March 13, 2013 and is headquartered in Philadelphia, PA.
52 Week High
52 Week Low
Research And Development
Yahoo FinanceMay 7
Will Spark Therapeutics (ONCE) Report Negative Q1 Earnings? What You Should Know
Wall Street expects a year-over-year increase in earnings on higher revenues when Spark Therapeutics (ONCE) reports results for the quarter ended March 2019. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.
Form SC TO-T/A Spark Therapeutics, Inc. Filed by: ROCHE HOLDINGS INC
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 5) SPARK THERAPEUTICS, INC. (Name of Subject Company) 022019 MERGER SUBSIDIARY, INC. (Offeror) A Wholly Owned Subsidiary of ROCHE HOLDINGS, INC. (Parent of Offeror) (Names of Filing Persons—Offeror) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 84652J103 (Cusip Number of ...
-$1.18 per share
Expected May 23, Pre-Market